Gossamer Bio's Post-Data-Flop Pivot: CT FRI Imaging and a Pragmatic FDA Path
After PROSERA missed its prespecified alpha, Gossamer leans on novel imaging evidence and a Type B pre-NDA meeting to push seralutinib toward submission.
GOSS · Earnings Call · 2026-05-18
After a Missed Statistical Bar, a Strategic Pivot
The February top-line readout from PROSERA, the Phase III study of seralutinib in pulmonary arterial hypertension (PAH), delivered a 13.3-meter placebo-adjusted improvement in six-minute walk distance (p=0.032) that cleared the conventional 0.05 threshold but missed the prespecified 0.025 alpha. The stock reacted violently, dropping over 60% in the subsequent 90 days, leaving Gossamer Bio (NASDAQ: GOSS) with a market cap of roughly $50 million. Yet on the Q1 2026 earnings call, management struck a defiant tone. “We believe the totality of the PROSERA data supports a real and clinically meaningful treatment signal.” — Faheem Hasnain, Chief Executive Officer · 2026-05-18 The company is not retreating; it is advancing an NDA submission under a regulatory framework that allows one adequate study plus confirmatory evidence. That decision is underpinned by three parallel work streams: a Type B pre-NDA meeting with the FDA, the analysis of a prespecified CT FRI (functional respiratory imaging) substudy, and a significant capital restructuring. The CT FRI data, in particular, are new and company-specific—they were the top keyword in the quarter and represent a mechanistic leap beyond typical vasodilator trials.CT FRI: First-of-its-Kind Reverse Remodeling Evidence
The PROSERA CT FRI substudy enrolled 162 patients, with 125 evaluable paired scans at week 24. Results showed statistically significant treatment effects across arterial, venous, and fibrosis-like parenchymal parameters. “This is the largest and most comprehensive CT FRI data set ever generated from a controlled therapeutic trial in pulmonary hypertension.” — Robert Roscigno, Unknown · 2026-05-18 Notably, seralutinib reduced fibrosis-like parenchymal volume—the first such demonstration in a controlled PAH trial—and increased venous blood volume, suggesting “venous vascular recovery.” CT FRI thus provides anatomical support for reverse remodeling, a claim no competing therapy has made. The commercial team is already leaning into this differentiator: “To my knowledge, we have not seen any other PAH therapy have this sort of information to clearly in humans show a strong reverse remodeling capability.” — Bob Smith, Unknown · 2026-05-18 These findings are not merely academic. They directly feed the NDA storyline. In Q&A, Caryn Peterson confirmed that the imaging data will be included in the NDA and could eventually appear in the pharmacodynamic section of the label, pending the June meeting. The data also reinforce the mechanistic plausibility of seralutinib’s inhibition of PDGFR, CSF1R, and c-KIT—pathways that drive vascular remodeling and fibrosis.Regulatory Path and Capital Stewardship
Gossamer has successfully upgraded its FDA interaction from a Type C to a more formal Type B pre-NDA meeting, which is scheduled for mid-June. The briefing book has been submitted, and the company reaffirmed its target NDA submission in September 2026, with potential approval in Q3 2027. Type B meeting and NDA submission are now central to the narrative, and management framed the decision as guided by external FDA advisers who see high unmet need and a compelling totality of evidence. On the capital side, the company acted decisively after the data miss. It cut roughly half its workforce, paused non-core programs, and executed a convertible note exchange that reduces outstanding debt from $200 million to $72 million on a fully subscribed basis, extending maturity to 2030. Bryan Giraudo stated: “We expect our cash runway to extend to the first quarter of 2027.” — Bryan Giraudo, Chief Operating Officer · 2026-05-18 This is a tight runway, but the cost reductions and lower quarterly burn are intended to bridge the company to an NDA filing and potential approval. The financial trajectory underscores the urgency. Research and Development expense of $43M in Q1 2026 is only slightly below the prior quarter’s $49M, but the reduction in force should meaningfully compress ongoing burn. Operational discipline is critical given that the company has yet to generate meaningful product revenue.From Confidence to Conviction
The contrast with the prior year’s call is stark. In May 2025, management was brimming with confidence about PROSERA’s design and patient enrollment. Faheem Hasnain declared: “Our focus is not to just achieve approvable results. That’s the bare minimum. Our focus is on generating comprehensive, definitive, and differentiated outcomes…” — Faheem Hasnain, Founder, Chairman, and Chief Executive Officer · 2025-05-15 Now, with the primary endpoint falling short of the strict alpha, the company has pivoted to a more pragmatic and arguably more risky regulatory strategy—relying on a “totality of evidence” argument and novel imaging endpoints that regulators have rarely used for approval decisions.Whether the FDA agrees remains the pivotal question. The stock’s collapse reflects skepticism, but the company’s insistence on moving forward—backed by the CT FRI data and a formalized regulatory meeting—sets up a binary event in the second half of 2026. For now, Gossamer is a name in motion: small-cap, high-risk, and uniquely levered to a single compound’s regulatory fate.Our conviction in seralutinib has increased since the top line readout, not decreased.